The FDA's recent decision to pull Pfizer Cox-2 inhibitor Bextra from the marketplace clearly jolted both Pfizer and the market. Pfizer was initially caught up in the Merck Vioxx dilemma months ago and its stock has declined from $38 per share a year ago to under $25 per share in February. It has recently moved up to the $27 level. This activity still represe